TITLE

Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up

AUTHOR(S)
Qin, YaZhen; Jiang, Bin; Jiang, Qian; Jiang, Hao; Li, JinLan; Zhang, Yan; Zhu, HongHu; Li, LingDi; Chen, ShanShan; Liu, YanRong; Huang, XiaoJun
PUB. DATE
January 2009
SOURCE
Annals of Hematology;Jan2009, Vol. 88 Issue 1, p37
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To explore the long-term efficacy of imatinib to chronic myeloid leukemia, a total of 46 late chronic phase (CP) patients were assessed after achieving complete cytogenetic response (CCyR). The median duration of imatinib treatment was 68 (61–74) months. Two hundred fifty-three bone marrow samples were detected BCR–ABL messenger RNA (mRNA) levels by TaqMan-based real-time quantitative reverse transcription–polymerase chain reaction. The median time when CCyR was first achieved was eight (3–72) months. Thirty-four patients achieved major molecular response (MMoR), and their median time when MMoR was first achieved was 35 (3–65) months. More patients achieving CCyR within 18 months obtained MMoR than those after 18 months (85% vs 42%, p = 0.006). One patient progressed into blastic crisis, and four patients suffered cytogenetic relapse later. The estimated 6-year event-free survival (EFS) rate of all patients was 81%. The BCR–ABL mRNA levels at the time of first CCyR of relapsed patients were significantly higher than those in continuous CCyR ( p = 0.011). The 6-year estimated EFS rate of MMoR patients was significantly higher than that of non-MMoR patients (100% vs 44%, p = 0.0001). Achieving CCyR within 18 months had a higher probability of achieving MMoR within 6 years. The 6-year estimated EFS rate was significantly higher for patients achieving CCyR within 12 months than those after 12 months (97% vs 55%, p = 0.05). The time when MMoR was first achieved did not affect 6-year estimated EFS. Therefore, imatinib could induce most late CP patients to achieve long-term durable responses after achieving CCyR. Both the time when CCyR was first achieved and the depth of BCR–ABL reduction after CCyR are relevant to long-term EFS.
ACCESSION #
35387719

 

Related Articles

  • Rapid diagnostic approach to PML-RARα-positive acute promyelocytic leukemia. Schoch, Claudia; Schnittger, Susanne; Kern, Wolfgang; Lengfelder, Eva; Löffler, Helmut; Hiddemann, Wolfgang; Haferlach, Torsten // Hematology Journal;2002, Vol. 3 Issue 5, p259 

    Introduction: Acute promyelocytic leukemia (APL) is a distinct entity characterized by a specific bone marrow morphology and a rearrangement of the PML- and the RARα-gene mostly due to a balanced translocation between the long arm of chromosome 15 with a breakpoint in 15q22 and the long arm...

  • The use of RT-PCR for the analysis of key loci in acute myeloid leukaemia. Grimwade, David // Journal of Medical Genetics;Sep2003 Supplement, Vol. 40, pS30 

    Cytogenetic and molecular characterisation of acute myeloid leukaemia (AML) has led to major advances in determining and optimising the treatment approach to patients with this disease. Cases of AML with t(15;17)(q22;q12-21), t(8;21)(q22;q22) and inv (16)(p13q22)/t(16;16)(p13;q22), which lead to...

  • JAK2 V617F MUTATION: A MARKER FOR CML PROGRESSION? MANJULA, G.; PRAJITHA, E. M.; SAILAJA, K.; RAGHUNADHA RAO, D.; ANURADHA, C.; SUGUNAKAR, V.; SANDHYA, A.; NAGESWARA RAO, D.; VISHNUPRIYA, S. // Journal of Cell & Tissue Research;2013, Vol. 13 Issue 1, p3439 

    Treatment with Imatinib mesylate leads to molecular remission in majority of Philadelphia chromosome (Ph) positive Chronic Myeloid Leukemia (CML) cases. However, sometimes persistent anemia or evolving myelofibrosis is observed due to a co-existing Ph negative chronic Myelo Proliferative...

  • Monitoring the Efficiency of Interferon-α Therapy in Chronic Myelogenous Leukemia (CML) Patients by Competitive Polymerase Chain Reaction. HOCHHAUS, Andreas; Feng LIN; REITER, Andreas; SKLADNY, Heyko; HEHLMANN, Rüdigger; GOLDMAN, John M.; CROSS, Nicholas C. P. // Leukemia (08876924);Apr97 Supplement 3, Vol. 11, p541 

    Interferon α (IFN-α) induces cytogenetic responses of variable degree in patients with CML. We sought to establish the relationship between BCR-ABL transcript numbers measured by competitive two-step reverse transcription polymerase chain reaction (RT-PCR) and cytogenetic status in CML...

  • Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukemia. Langabeer, S.E.; Gale, R.E.; Harvey, R.C.; Cook, R.W.; Mackinnon, S.; Linch, D.C. // Leukemia (08876924);Mar2002, Vol. 16 Issue 3, p393 

    Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) is used to confirm the diagnosis and to monitor residual disease. Quantitative techniques are required to predict response to therapy or early relapse. We have evaluated an assay in which transcription-mediated amplification...

  • CHRONIC MYELOID LEUKEMIA WITH HYPERDIPLOIDY: A CASE REPORT WITH REVIEW OF LITERATURE. BELURKAR, SUSHMA; MANOHAR, CHETHAN; KURIEN, ANNAMMA // Indian Journal of Medical Sciences;Jul/Aug2013, Vol. 67 Issue 7/8, p188 

    Chronic myeloid leukemia (CML) is a common marrow stem cell neoplasm characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. Studies have shown that CML can be associated with various other cytogenetic abnormalities. 5-10% of these cases can show complex...

  • Stopping Imatinib: When is Enough Enough? Ershler, William B. // Clinical Oncology Alert;Sep2013, Vol. 29 Issue 9, p71 

    The article discusses the study regarding the discontinuation of the Imatinib therapy. The author states that the study is a significant contribution because it affirms the results from the trial of Stop Imatinib (STIM) which shows that it can be discontinued safely to patients with maintained...

  • Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy. Martinelli, G; Testoni, N; Amabile, M; Bonifazi, F; De Vivo, A; Farabegoli, P; Terragna, C; Montefusco, V; Ottaviani, E; Saglio, G; Russo, D; Baccarani, M; Rosti, G; Tura, S // Bone Marrow Transplantation;4/1/2000, Vol. 25 Issue 7, p729 

    We measured using a competitive quantitative polymerase chain reaction-capillary electrophoresis (PCR-CE)-based assay, the levels of bcr-abl transcripts in 44 patients with chronic myeloid leukemia (CML) after interferon-α (IFN-α) therapy, who achieved a major (10 patients, MCR group) or...

  • A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Fasan, A; Haferlach, C; Alpermann, T; Kern, W; Haferlach, T; Schnittger, S // Leukemia (08876924);Jan2013, Vol. 27 Issue 1, p245 

    The article discusses the detection of cytogenetically cryptic NUP98-NSD1 fusion gene in a specific subset of adult acute myeloid leukemia (AML) patients. Cytogenetically detectable chromosomal rearrangement leads to fusion genes in AML cases. The study involved evaluation of NUP98–NSD1...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics